Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Chime Biologics Partners with Leads Biolabs and BeiGene | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Chime Biologics Partners with Leads Biolabs and BeiGene

Alliance aims to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.

By: Anthony Vecchione

Chime Biologics, a biologics contract development and manufacturing organization (CDMO), has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.

LBL-007 is a novel antibody targeting the LAG-3 pathway developed independently by Leads Biolabs.

Previously, Leads Biolabs and BeiGene reached an authorization and cooperation agreement. Leads Biolabs grants LBL-007 exclusive global development and production license to BeiGene, as well as a commercial manufacturing license outside China.

Leads Biolabs has entrusted Chime Biologics with the file supporting work related to the production of LBL-007 project and clinical trial materials in mainland China. Now, the project is progressing into clinical phase II stage. Leads Biolabs is evaluating the safety and efficacy of anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 in the treatment of advanced or metastatic melanoma.

Chime Biologics will provide support for clinical development and manufacturing of clinical trial materials to facilitate multiple clinical trials. The indications encompass colorectal cancer, non-small cell lung cancer, head, and neck squamous cell carcinoma, as well as other solid tumors.

The three parties have established a comprehensive strategic partnership to help rapidly advance multiple clinical studies and the global development distribution of LBL-007.  


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics